6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US8101613B2 · kind B2 · utility
6Cited by
26References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 12, 2009 |
| Grant date | Jan 24, 2012 |
| Priority date | — |
| Expiry date | Aug 12, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of the formulaand pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.